Introduction: Landau-Kleffner Syndrome is a rare childhood disorder characterized by acquired aphasia and epileptiform EEG abnormalities. Hyperactivity and attention problems are common in LKS, and symptoms of Autism Spectrum Disorders (ASDs) may also coexist. Many different treatments have been used for LKS, with varying rates of success. In particular, the effects of antiepileptic drug treatment on acquisition of language have been inconsistent. To the best of our knowledge the literature does not include any reports on the effect of antiepileptic drug treatment on ASD symptoms in patients with LKS. Herein we report a boy with LKS whose ASD symptoms markedly improved in response to antiepileptic treatment.

Case: A boy aged 3 years 10 months presented to the department of child and adolescent psychiatry due to lack of social interaction, decreased eye contact, stereotypic hand movements, and language regression. The patient was diagnosed as LKS and valproic acid (VAL) treatment was started. The patient was followed-up regularly and after 3 months of treatment with VAL substantial improvement was observed in problematic behaviors, and language and social skills.

Discussion: In the presented LKS case rapid improvement in autism symptoms was observed in response to antiepileptic drug treatment. The patient's reacquisition of speech and rapid improvement in social skills with antiepileptic treatment are important findings. It may be possible to effectively treat ASD symptoms in patients with LKS with early diagnosis and appropriate antiepileptic treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antiepileptic treatment
12
antiepileptic drug
12
drug treatment
12
asd symptoms
12
symptoms patients
8
patients lks
8
response antiepileptic
8
rapid improvement
8
antiepileptic
7
lks
7

Similar Publications

Background: The imbalance of glutamate (Glu) and gamma-aminobutyric acid (GABA) neurotransmitter system plays a crucial role in the pathogenesis of Alzheimer's disease (AD). Riluzole is a Glu modulator originally approved for amyotrophic lateral sclerosis that has shown potential neuroprotective effects in various neurodegenerative disorders. However, whether riluzole can improve Glu and GABA homeostasis in AD brain and its related mechanism of action remain unknown.

View Article and Find Full Text PDF

Importance: How epilepsy may promote cardiovascular disease remains poorly understood.

Objective: To estimate the odds of new-onset cardiovascular events (CVEs) over 6 years in older people with vs without epilepsy, exploring how enzyme-inducing antiseizure medications (EIASMs) and traditional cardiovascular risk factors mediate these odds.

Design, Setting, And Participants: This was a prospective cohort study using the comprehensive cohort of the Canadian Longitudinal Study on Aging (CLSA), with 6 years of follow-up (2015-2021, analysis performed in December 2023).

View Article and Find Full Text PDF

Complex regional pain syndrome (CRPS) is a chronic pain disorder characterized by severe, disproportionate pain relative to an inciting event. The disorder's pathophysiology is complex, involving both central and peripheral nervous system alterations, alongside genetic, inflammatory, and psychological factors. Using data from TriNetX, this study investigated the impact of analgesic and adjuvant therapies on psychiatric outcomes in CRPS patients.

View Article and Find Full Text PDF

Super-refractory status epilepticus (SRSE) is defined as status epilepticus that persists or recurs after treatment with anesthetic agents for more than 24 hours, including cases with recurrent seizures on reduction or withdrawal of anesthetic drugs. Super-refractory status epilepticus presents a significant challenge for neurologists, particularly when standard treatments fail to achieve seizure control. Lacosamide, which has a unique mechanism involving modulating voltage-gated sodium channels by enhancing their slow inactivation, has emerged as a potential option for managing SRSE.

View Article and Find Full Text PDF

There is a lack of objective indicators to evaluate the treatment effect of burning mouth syndrome, a neuropathic pain of unknown causes. Therefore, this study aimed to evaluate potential salivary biomarkers by analyzing saliva before and after clonazepam treatment in patients with burning mouth syndrome. Saliva was collected from 23 patients with burning mouth syndrome before and 4 weeks after the topical administration of clonazepam.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!